Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of age

Bone Marrow Transplantation volume 32, pages 1135–1143 (2003)Cite this article

Summary:

The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patients ⩾the age of 60 (median 63; range 60–73) years, undergoing AuSCT with that of 382 patients <60 (median 52; range 30–59) years. The two groups were similar except that older patients had a higher β2-microglobulin level at diagnosis (P=0.016) and fewer had lytic lesions (P=0.007). Day 100 mortality was 6% (95% confidence interval 4–9) and 1-year treatment-related mortality (TRM) was 9% (6–13) in patients <60 years, compared with 5% (2–10) and 8% (4–14), respectively, in patients ⩾60 years. The relapse rate, progression-free survival (PFS) and overall survival (OS) in the two groups were also similar. Multivariate analysis of all patients identified only an interval from diagnosis to AuSCT >12 months and the use of two prior chemotherapy regimens within 6 months of AuSCT as adverse prognostic factors. Our results indicate that AuSCT can be safely performed in selected older patients: the best results were observed in patients undergoing AuSCT relatively early in their disease course.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  2. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793.

    CAS  PubMed  Google Scholar 

  3. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high dose therapy with autologous stem cell transplant support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7–11.

    CAS  PubMed  Google Scholar 

  4. Harousseau JL, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077–3085.

    CAS  PubMed  Google Scholar 

  5. Leger CS, Bredeson C, Kewarns B et al. Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant 2000; 6: 204–210.

    Article  CAS  PubMed  Google Scholar 

  6. De la Rubia J, Sadverdra S, Sauz GF et al. Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 21–25.

    Article  CAS  PubMed  Google Scholar 

  7. Palumbo A, Triolo S, Argentino C et al. Dose-intensive melphalan with stem cell support (MEL 100) is superior to standard treatment in elderly myeloma patient's blood. Blood 1999; 94: 1248–1253.

    CAS  PubMed  Google Scholar 

  8. Siegel DS, Desikan KR, Mehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51–54.

    CAS  PubMed  Google Scholar 

  9. Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600–607.

    Article  CAS  PubMed  Google Scholar 

  10. Sirohi B, Powles R, Treleaven J et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533–539.

    Article  CAS  PubMed  Google Scholar 

  11. Dumontet C, Ketterer N, Espinouse D et al. Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell vein fusion for multiple myeloma. Bone Marrow Transplant 1998; 21: 1037–1041.

    Article  CAS  PubMed  Google Scholar 

  12. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123.

    Article  CAS  PubMed  Google Scholar 

  13. Gooley A, Leisenring W, Crowley J et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706.

    Article  CAS  PubMed  Google Scholar 

  14. Klein JP, Moeschberger ML . Survival Analysis: Techniques for Censored and Truncated Data. Springer-Verlag: New York, NY, 1997.

    Book  Google Scholar 

  15. Andersen PK, Klein JP, Zhang MH . Testing for center effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med 1999; 18: 1489–1500.

    Article  CAS  PubMed  Google Scholar 

  16. Vesole DH, Tricot G, Jagannath S et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996; 88: 838–847.

    CAS  PubMed  Google Scholar 

  17. Moreau P, Facon T, Attal M et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM 95-02 randomized trial. Blood 2002; 99: 731–735.

    Article  CAS  PubMed  Google Scholar 

  18. Bjorkstrand B, Svensson G, Goldschmidt H et al. Autotransplants in multiple myeloma: a registry from the European Group for Blood and Marrow Transplantation (EBMT). Blood 1999; 94 (Suppl 1): 714a (abstract 3154).

    Google Scholar 

  19. Cunningham D, Powles R, Malpas J et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1999; 102: 495–502.

    Article  Google Scholar 

  20. Berenson JR, Crowley JJ, Grogan TM et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99: 3163–3168.

    Article  CAS  PubMed  Google Scholar 

  21. Alexanian R, Weber D, Giralt S et al. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 2002; 13: 1116–1119.

    Article  CAS  PubMed  Google Scholar 

  22. Rufffini PA, Kwak LW . Immunotherapy of multiple myeloma. Sem Hematol 2001; 38: 260–267.

    Article  Google Scholar 

  23. Hideshima T, Chuhan D, Podar K et al. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001; 28: 607–612.

    Article  CAS  PubMed  Google Scholar 

  24. Maloney DG, Sahebi F, Stockerl-Goldstein KE et al. Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma. Presentation at the American Society of Hematology 43rd Annual Meeting and Exposition. Blood 2001; 98 (Part 1 of 2) 434a–435a (abstract 1822).

    Google Scholar 

Download references

Acknowledgements

This work was supported by Public Health Service Grant U24-CA76518 from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung and Blood Institute, and grants from Abgenix, Inc.; AmCell Corporation; American Cancer Society; American Society of Clinical Oncology; Amgen, Inc.; Anonymous; Aventis Pharmaceuticals; Berlex Laboratories; BioTransplant, Incorporated; Blue Cross and Blue Shield Association; Lynde and Harry Bradley Foundation; Bristol-Myers Squibb Oncology; CelMed Biosciences; Center for Advanced Studies in Leukemia; Cerus Corporation; Chimeric Therapies; Chiron Therapeutics; Eleanor Naylor Dana Charitable Trust; Deborah J Dearholt Memorial Fund; Edwards Lifesciences RMI; Empire Blue Cross Blue Shield; Fujisawa Healthcare, Inc.; Gambro BCT, Inc.; Genentech, Inc.; GlaxoSmithKline, Inc.; Human Genome Sciences; ICN Pharmaceuticals, Inc.; IDEC Pharmaceuticals Corporation; IntraBiotics Pharmaceuticals; Kettering Family Foundation; Kirin Brewery Company; Robert J Kleberg, Jr and Helen C Kleberg Foundation; LifeTrac/Allianz; Eli Lilly and Company; The Liposome Company; Nada and Herbert P Mahler Charities; Market Certitude, LLC; Mayer Ventures; MedImmune, Inc.; Merck & Co., Inc.; Milliman & Robertson, Inc.; Milstein Family Foundation; The Greater Milwaukee Foundation/Elsa Schoeneich Research Fund; NeoRx; Nexell Therapeutics; Novartis Pharmaceuticals; Orphan Medical; Ortho Biotech, Inc.; John Oster Family Foundation; Osiris Therapeutics, Inc.; Pfizer US Pharmaceuticals; Pharmacia Corporation; Pharmametrics GmbH; Principal Life Insurance Company; Protein Design Labs, Inc.; Response Oncology, Inc.; RGK Foundation; Roche Laboratories, Inc.; SangStat; Schering AG; Schering Oncology/Biotech; Stackner Family Foundation; The Starr Foundation; SuperGen, Inc.; TheraTechnologies, Inc.; Unicare Life & Health Insurance; Wyeth/Genetics Institute and ZymoGenetics, Inc. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

Author information

Authors and Affiliations

  1. Princess Margaret Hospital, Toronto, Ontario, Canada

    D E Reece & A Keating

  2. Autologous Blood and Marrow Transplant Registry (ABMTR), Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI, USA

    C Bredeson, W S Pérez, M J Zhang & D H Vesole

  3. St Vincent's Hospital Manhattan Center, New York, NY, USA

    S Jagannath

  4. University of Massachusetts Medical Center, Worcester, MA, USA

    K K Ballen

  5. Roger Williams Medical Center, Providence, RI, USA

    G J Elfenbein

  6. University of Texas Health Science Center, San Antonio, TX, USA

    C O Freytes

  7. Center for Advanced Studies in Leukemia, Los Angeles, CA, USA

    R P Gale

  8. Mayo Clinic, Rochester, MN, USA

    M A Gertz & R A Kyle

  9. Royal Prince Alfred Hospital, Camperdown, NSW, Australia

    J Gibson

  10. MD Anderson Cancer Center, Houston, TX, USA

    S A Giralt

  11. Bethesda Health City Bone Marrow Transplant Institute, Boynton Beach, FL, USA

    D Maharaj

  12. Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada

    D Marcellus

  13. Roswell Park Cancer Institute, Buffalo, NY, USA

    P L McCarthy

  14. Angélica Ocampo-Hospital and Research Center-Fundaleu, Buenos Aires, Argentina

    G A Milone & S Pavlovsky

  15. Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    S D Nimer

  16. Hanson Centre for Cancer Research, Adelaide, South Australia, Australia

    L B To

  17. University of Minnesota, Minneapolis, MN, USA

    D J Weisdorf

  18. New York Medical College, Bronx, NY, USA

    P H Wiernik

  19. University of Florida College of Medicine, Gainesville, FL, USA

    J R Wingard

Authors
  1. D E Reece
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Bredeson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W S Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Jagannath
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M J Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K K Ballen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G J Elfenbein
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C O Freytes
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R P Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M A Gertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Gibson
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S A Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. R A Kyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. D Maharaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. D Marcellus
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. P L McCarthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. G A Milone
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. S D Nimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. S Pavlovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. L B To
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. D J Weisdorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. P H Wiernik
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. J R Wingard
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. D H Vesole
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reece, D., Bredeson, C., Pérez, W. et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of age. Bone Marrow Transplant 32, 1135–1143 (2003). https://doi.org/10.1038/sj.bmt.1704288

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704288

Keywords

This article is cited by

Search

Advanced search

Quick links